GlassScriptPhysician profile
Melissa Davis
NPI 1700372596
$2,204.72
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $473 · 2023: $608 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.01 | 2021-2024 | |
| Lilly USA, LLC | $277.61 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.20 | 2021-2023 | Jardiance |
| Dexcom, INC. | $120.76 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $105.17 | 2021-2022 | |
| Gilead Sciences, INC. | $97.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $96.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.11 | 2022 | |
| Biogen, INC. | $70.07 | 2024 | |
| Amgen INC. | $58.33 | 2022-2024 | Evenity, Prolia |
| Exact Sciences Corporation | $52.68 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $47.01 | 2022-2023 | Breztri |
| Merck Sharp & Dohme LLC | $37.14 | 2021 | |
| Almatica Pharma LLC | $33.99 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.81 | 2022-2023 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.23 | 2023 | Xifaxan |
| Corcept Therapeutics | $27.25 | 2022 | |
| Mdd US Operations, LLC | $26.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.84 | 2022 | |
| Abbott Laboratories | $23.63 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $20.30 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $18.53 | 2023 | Xarelto |
| Pfizer INC. | $17.05 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.58 | 2023 | Qelbree |
| Alexion Pharmaceuticals, INC. | $15.34 | 2023 | Ultomiris |
| Eisai INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.